Roivant Sciences Ltd. (ROIV)
Every FINRA and SEC series the site collects for Roivant Sciences Ltd.: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
30.6M
Short interest
settlement 2026-08-14
5.0
Days to cover
-13.2% vs prior
58.5%
Short share of volume
2026-09-11
575
Fails to deliver
settlement 2026-06-30
-$50.7M
Insider flow, 90 days
0 buys, 10 sells
As of 2026-09-11.
Short interest
FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSONAs of 14 August 2026, short interest in ROIV is 30,601,726 shares, down 6,093,832 shares over the last month. Over the last 48 readings it ranged from 17,520,355 shares (15 December 2025) to 52,735,015 shares (30 April 2025). At the reported average volume of 6.1M shares a day that is 5.0 days to cover, elevated.
Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/roiv" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-14 | 30,601,726 | -13.2% | 6,103,989 | 5.01 |
| 2026-07-31 | 35,233,818 | -4.0% | 4,407,819 | 7.99 |
| 2026-07-15 | 36,695,558 | +10.5% | 4,798,919 | 7.65 |
| 2026-06-30 | 33,212,917 | -0.1% | 7,782,780 | 4.27 |
| 2026-06-15 | 33,244,439 | -8.3% | 4,423,546 | 7.52 |
| 2026-05-29 | 36,233,835 | +32.4% | 8,748,838 | 4.14 |
| 2026-05-15 | 27,377,524 | +1.2% | 4,807,466 | 5.69 |
| 2026-04-30 | 27,055,375 | +10.6% | 5,595,903 | 4.83 |
| 2026-04-15 | 24,470,022 | -1.7% | 4,229,831 | 5.79 |
| 2026-03-31 | 24,884,496 | +6.4% | 5,793,424 | 4.30 |
| 2026-03-13 | 23,387,772 | -0.3% | 6,440,939 | 3.63 |
| 2026-02-27 | 23,457,731 | +5.3% | 4,598,282 | 5.10 |
| 2026-02-13 | 22,266,323 | -4.4% | 9,170,829 | 2.43 |
| 2026-01-30 | 23,288,019 | -5.1% | 4,582,244 | 5.08 |
| 2026-01-15 | 24,529,353 | +25.3% | 6,681,612 | 3.67 |
| 2025-12-31 | 19,579,958 | +11.8% | 7,948,165 | 2.46 |
| 2025-12-15 | 17,520,355 | -16.2% | 7,915,441 | 2.21 |
| 2025-11-28 | 20,914,523 | -9.3% | 5,699,020 | 3.67 |
| 2025-11-14 | 23,049,893 | -6.0% | 9,547,574 | 2.41 |
| 2025-10-31 | 24,528,207 | -2.9% | 8,812,288 | 2.78 |
| 2025-10-15 | 25,271,869 | -9.6% | 6,660,670 | 3.79 |
| 2025-09-30 | 27,966,982 | -22.8% | 9,744,740 | 2.87 |
| 2025-09-15 | 36,208,272 | -7.3% | 9,353,784 | 3.87 |
| 2025-08-29 | 39,048,414 | +2.5% | 4,041,413 | 9.66 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 11 September 2026, the short share of ROIV volume is 58.5%, down 7.1 points over the last five sessions. Over the last 52 readings it ranged from 27.7% (21 July 2026) to 67.5% (14 August 2026). The latest reading is 6.3 points above the 30-session average of 52.2%, on 2.9M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-11 | 1.7M | 2.9M | 58.5% | 10,768 |
| 2026-09-10 | 1.8M | 2.8M | 62.8% | 1,297 |
| 2026-09-09 | 2.2M | 4.2M | 52.6% | 28,213 |
| 2026-09-08 | 6.4M | 11.5M | 55.6% | 93,490 |
| 2026-09-04 | 1.3M | 2.2M | 61.3% | 23,016 |
| 2026-09-03 | 802K | 1.2M | 65.6% | 881 |
| 2026-09-02 | 867K | 1.9M | 45.3% | 100 |
| 2026-09-01 | 1.1M | 1.8M | 62.6% | 214 |
| 2026-08-31 | 1.8M | 3.3M | 53.0% | 0 |
| 2026-08-28 | 2.2M | 3.8M | 57.3% | 123,973 |
| 2026-08-27 | 1.4M | 2.3M | 60.7% | 4,232 |
| 2026-08-26 | 997K | 2.1M | 47.4% | 175 |
| 2026-08-25 | 826K | 1.9M | 42.5% | 0 |
| 2026-08-24 | 761K | 2.1M | 35.7% | 8,000 |
| 2026-08-21 | 764K | 2.6M | 28.8% | 0 |
| 2026-08-20 | 603K | 1.1M | 54.7% | 0 |
| 2026-08-19 | 1.2M | 2.0M | 61.6% | 5,681 |
| 2026-08-18 | 1.2M | 2.0M | 61.0% | 10,000 |
| 2026-08-17 | 978K | 1.8M | 53.6% | 0 |
| 2026-08-14 | 939K | 1.4M | 67.5% | 7,216 |
| 2026-08-13 | 962K | 1.5M | 65.9% | 5 |
| 2026-08-12 | 778K | 2.2M | 35.0% | 11,179 |
| 2026-08-11 | 1.1M | 2.1M | 53.2% | 0 |
| 2026-08-10 | 919K | 2.7M | 34.5% | 9,755 |
| 2026-08-07 | 1.5M | 2.9M | 50.9% | 12,023 |
| 2026-08-06 | 1.2M | 2.6M | 48.2% | 275 |
| 2026-08-05 | 1.2M | 2.2M | 52.1% | 2,843 |
| 2026-08-04 | 774K | 1.5M | 52.1% | 15 |
| 2026-08-03 | 1.1M | 2.3M | 49.3% | 2,391 |
| 2026-07-31 | 678K | 1.9M | 35.7% | 5,031 |
Fails to deliver
SEC, by settlement date. JSONAs of 30 June 2026, the fails-to-deliver balance in ROIV is 575 shares, down 448,135 shares over the last settlement date. Over the last 42 readings it ranged from 3 shares (4 December 2025) to 1,399,610 shares (20 February 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-06-30 | 575 | $34.73 | $20K |
| 2026-06-29 | 448,710 | $34.07 | $15.3M |
| 2026-06-22 | 2,227 | $31.43 | $70K |
| 2026-06-15 | 12,109 | $30.04 | $364K |
| 2026-06-08 | 30,276 | $28.58 | $865K |
| 2026-06-01 | 38,910 | $29.99 | $1.2M |
| 2026-04-27 | 9 | $27.41 | $247 |
| 2026-04-17 | 612,895 | $29.19 | $17.9M |
| 2026-04-06 | 668 | $28.33 | $19K |
| 2026-03-31 | 122 | $26.41 | $3K |
| 2026-03-26 | 266 | $27.36 | $7K |
| 2026-03-25 | 49 | $26.87 | $1K |
| 2026-03-23 | 28 | $27.70 | $776 |
| 2026-03-03 | 2,411 | $28.10 | $68K |
| 2026-02-23 | 1,055,638 | $27.15 | $28.7M |
| 2026-02-20 | 1,399,610 | $27.52 | $38.5M |
| 2026-02-19 | 24 | $27.48 | $660 |
| 2026-02-18 | 6 | $27.09 | $163 |
| 2026-01-23 | 2,152 | $22.97 | $49K |
| 2026-01-09 | 59 | $21.78 | $1K |
| 2026-01-08 | 32 | $21.98 | $703 |
| 2025-12-31 | 2,876 | $21.63 | $62K |
| 2025-12-30 | 2,642 | $21.70 | $57K |
| 2025-12-23 | 3,674 | $22.68 | $83K |
| 2025-12-22 | 56 | $22.41 | $1K |
| 2025-12-19 | 122 | $21.79 | $3K |
| 2025-12-10 | 15,513 | $20.43 | $317K |
| 2025-12-04 | 3 | $20.70 | $62 |
| 2025-12-01 | 500 | $20.81 | $10K |
| 2025-11-24 | 1,800 | $20.22 | $36K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at ROIV reported 10 open-market sells worth $50.7M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Venker Eric (President & Immunovant CEO) on 2026-08-28.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-28 | Venker Eric | President & Immunovant CEO | Sell | 34K | $36.44 | $1.2M | 1.6M |
| 2026-08-28 | Venker Eric | President & Immunovant CEO | Sell | 166K | $35.63 | $5.9M | 1.6M |
| 2026-08-28 | Venker Eric | President & Immunovant CEO | Option exercise | 200K | $3.85 | $770K | 1.8M |
| 2026-08-21 | Sukhatme Mayukh | President & CIO | Sell | 145K | $36.48 | $5.3M | 18.6M |
| 2026-08-21 | Sukhatme Mayukh | President & CIO | Option exercise | 145K | $3.85 | $557K | 18.8M |
| 2026-08-20 | Venker Eric | President & Immunovant CEO | Tax withholding | 14K | $36.84 | $512K | 1.6M |
| 2026-08-20 | Pulik Richard | CFO | Tax withholding | 6K | $36.84 | $212K | 272K |
| 2026-08-20 | Sukhatme Mayukh | President & CIO | Sell | 18K | $37.30 | $653K | 18.6M |
| 2026-08-20 | Sukhatme Mayukh | President & CIO | Option exercise | 18K | $3.85 | $67K | 18.6M |
| 2026-08-19 | Sukhatme Mayukh | President & CIO | Sell | 173K | $37.17 | $6.4M | 18.6M |
| 2026-08-19 | Sukhatme Mayukh | President & CIO | Option exercise | 173K | $3.85 | $666K | 18.8M |
| 2026-08-18 | Sukhatme Mayukh | President & CIO | Sell | 32K | $37.18 | $1.2M | 18.6M |
| 2026-08-18 | Sukhatme Mayukh | President & CIO | Option exercise | 32K | $3.85 | $122K | 18.7M |
| 2026-08-18 | Sukhatme Mayukh | President & CIO | Sell | 105K | $36.59 | $3.8M | 18.6M |
| 2026-08-18 | Sukhatme Mayukh | President & CIO | Option exercise | 105K | $3.85 | $405K | 18.7M |
| 2026-08-17 | Sukhatme Mayukh | President & CIO | Sell | 285K | $36.25 | $10.3M | 18.6M |
| 2026-08-17 | Sukhatme Mayukh | President & CIO | Option exercise | 285K | $3.85 | $1.1M | 18.9M |
| 2026-08-14 | Sukhatme Mayukh | President & CIO | Sell | 243K | $36.23 | $8.8M | 18.6M |
| 2026-08-14 | Sukhatme Mayukh | President & CIO | Option exercise | 243K | $3.85 | $936K | 18.9M |
| 2026-07-27 | Venker Eric | President & Immunovant CEO | Sell | 200K | $34.95 | $7.0M | 1.6M |
| 2026-07-27 | Venker Eric | President & Immunovant CEO | Option exercise | 200K | $3.85 | $770K | 1.8M |
| 2026-07-17 | Epperly Melissa B, | n/a | Grant | 543 | $0.00 | $0 | 17K |
| 2026-05-22 | Venker Eric | President & Immunovant CEO | Sell | 200K | $30.27 | $6.1M | 1.6M |
| 2026-05-22 | Venker Eric | President & Immunovant CEO | Option exercise | 200K | $3.85 | $770K | 1.8M |
| 2026-05-20 | Venker Eric | President & Immunovant CEO | Tax withholding | 34K | $32.41 | $1.1M | 1.6M |
| 2026-05-20 | Pulik Richard | CFO | Tax withholding | 19K | $32.41 | $615K | 279K |
| 2026-04-20 | Venker Eric | President & Immunovant CEO | Sell | 200K | $29.59 | $5.9M | 1.6M |
| 2026-04-20 | Venker Eric | President & Immunovant CEO | Option exercise | 200K | $3.85 | $770K | 1.8M |
| 2026-04-20 | Pulik Richard | CFO | Grant | 61K | $0.00 | $0 | 298K |
| 2026-04-20 | Humes Jennifer | Chief Accounting Officer | Grant | 29K | $0.00 | $0 | 113K |
| 2026-04-17 | Oren Ilan | n/a | Tax withholding | 95 | $29.83 | $3K | 120K |
| 2026-04-17 | Oren Ilan | n/a | Grant | 896 | $0.00 | $0 | 120K |
| 2026-04-17 | MOMTAZEE JAMES C | n/a | Tax withholding | 94 | $29.83 | $3K | 109K |
| 2026-04-17 | MOMTAZEE JAMES C | n/a | Grant | 469 | $0.00 | $0 | 109K |
| 2026-04-17 | Epperly Melissa B, | n/a | Grant | 670 | $0.00 | $0 | 16K |
| 2026-04-16 | Gline Matthew | CEO | Sell | 290K | $29.16 | $8.4M | 16.7M |
| 2026-04-08 | Humes Jennifer | Chief Accounting Officer | Sell | 14K | $28.37 | $384K | 84K |
| 2026-03-31 | Torti Frank | President and Vant Chair | Tax withholding | 160K | $27.70 | $4.4M | 13.6M |
| 2026-03-26 | Fitzgerald Meghan | n/a | Sell | 70K | $27.45 | $1.9M | 43K |
| 2026-03-26 | Fitzgerald Meghan | n/a | Option exercise | 70K | $8.80 | $616K | 113K |
| 2026-03-20 | Pulik Richard | CFO | Tax withholding | 2K | $27.70 | $43K | 237K |
| 2026-03-20 | Humes Jennifer | Chief Accounting Officer | Tax withholding | 15K | $27.70 | $402K | 98K |
| 2026-03-17 | Venker Eric | President & Immunovant CEO | Sell | 200K | $28.24 | $5.6M | 1.6M |
| 2026-03-17 | Venker Eric | President & Immunovant CEO | Option exercise | 200K | $3.85 | $770K | 1.8M |
| 2026-03-16 | Epperly Melissa B, | n/a | Sell | 42K | $28.68 | $1.2M | 16K |
| 2026-02-23 | Torti Frank | President and Vant Chair | Sell | 587K | $27.51 | $16.2M | 13.7M |
| 2026-02-23 | Torti Frank | President and Vant Chair | Option exercise | 587K | $3.85 | $2.3M | 14.3M |
| 2026-02-20 | Torti Frank | President and Vant Chair | Sell | 1.0M | $27.15 | $27.5M | 13.7M |
| 2026-02-20 | Torti Frank | President and Vant Chair | Option exercise | 1.0M | $3.85 | $3.9M | 14.7M |
| 2026-02-20 | Venker Eric | President & Immunovant CEO | Tax withholding | 7K | $27.15 | $191K | 1.6M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
Planned sales (Form 144)
Newest first. JSON8 Form 144 notices on file for ROIV worth $42.5M at the prices reported; 8 in the last 90 days worth $42.5M. Latest: MEGHAN FITZGERALD filed on 2026-09-08 to sell 20,000 shares ($699K) from 2026-09-08.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-08 | MEGHAN FITZGERALDDirector | 20K | $699K | 0.003% | 2026-09-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-28 | Venker EricOfficer | 200K | $7.1M | 0.028% | 2026-08-28 | Rockefeller Financial LLC |
| 2026-08-21 | MAYUKH SUKHATMEOfficer, Director | 145K | $5.3M | 0.020% | 2026-08-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-20 | MAYUKH SUKHATMEOfficer, Director | 18K | $653K | 0.002% | 2026-08-20 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-19 | MAYUKH SUKHATMEOfficer, Director | 173K | $6.4M | 0.024% | 2026-08-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-18 | MAYUKH SUKHATMEOfficer, Director | 137K | $5.0M | 0.019% | 2026-08-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-17 | MAYUKH SUKHATMEOfficer, Director | 285K | $10.3M | 0.039% | 2026-08-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-27 | Venker EricOfficer | 200K | $7.0M | 0.028% | 2026-07-27 | Rockefeller Financial LLC |
13F holders
Tracked managers holding ROIV at their latest 13F. JSON9 of the 30 tracked managers held ROIV at their latest 13F, $1.03B in total at quarter-end prices. AQR Capital Management is the largest at $234.0M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 6.6M | $234.0M | 0.08% | +687K |
| Viking Global Investors | 2026-06-30 | 6.3M | $221.9M | 0.63% | -381K |
| Citadel Advisors | 2026-06-30 | 5.8M | $205.7M | 0.02% | +3.1M |
| Point72 Asset Management | 2026-06-30 | 4.5M | $159.1M | 0.18% | +3.5M |
| D. E. Shaw & Co. | 2026-06-30 | 3.0M | $105.2M | 0.05% | +1.6M |
| Greenlight Capital (DME Capital) | 2026-06-30 | 2.2M | $76.2M | 1.95% | 0 |
| Millennium Management | 2026-06-30 | 700K | $24.8M | 0.01% | -103K |
| Two Sigma Investments | 2026-06-30 | 22K | $779K | 0.00% | +10K |
| Fisher Asset Management | 2026-06-30 | 16K | $563K | 0.00% | new or n/a |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 2026 (quarter ended 2026-06-30) Roivant Sciences Ltd. reported revenue of $1.4M, down 33.5% from the same quarter a year earlier, and net loss of $189.8M (-0.26 diluted EPS). In FY 2025 it generated -$750.3M of operating cash flow.
- Cash
- $1.25B
- Equity
- $4.23B
- Total assets
- $5.31B
- Shares outstanding
- 722,323,015
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.4M | -$189.8M | -13164.8% | -0.26 |
| Q4 2025derived | 2026-03-31 | $2.5M | $303.0M | 12023.6% | n/a |
| Q4 2025 | 2025-12-31 | $2.0M | -$265.9M | -13301.2% | -0.38 |
| Q3 2025 | 2025-09-30 | $1.6M | -$113.5M | -7225.9% | -0.17 |
| Q2 2025 | 2025-06-30 | $2.2M | -$223.4M | -10292.9% | -0.33 |
| Q4 2024derived | 2025-03-31 | $7.6M | -$206.5M | -2727.5% | n/a |
| Q4 2024 | 2024-12-31 | $9.0M | $169.4M | 1878.3% | 0.23 |
| Q3 2024 | 2024-09-30 | $4.5M | -$230.2M | -5143.8% | -0.31 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2026-03-31 | $8.3M | -$299.8M | -$750.3M | $8.2M | n/a | n/a |
| FY 2024 | 2025-03-31 | $29.1M | -$172.0M | -$839.5M | $4.6M | $1.29B | n/a |
| FY 2023 | 2024-03-31 | $32.7M | $4.35B | -$765.3M | $1.4M | $0 | n/a |
| FY 2022 | 2023-03-31 | $31.5M | -$1.01B | -$843.4M | $12.7M | $0 | n/a |
| FY 2021 | 2022-03-31 | $55.3M | -$845.3M | -$677.7M | $17.4M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Roivant Sciences Ltd. in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows Roivant Sciences Ltd. (ROIV), SEC CIK 1635088, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-06-30.JSON and CSV
- Planned sales
- SEC EDGAR Form 144EDGAR read every 30 minutes; a notice is filed on or before the sell order. Latest 2026-09-08.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-08-28.JSON and CSV
- Company record
- EDGAR filing index for CIK 1635088Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 13 Sep 05:40 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
- UTHRUNITED THERAPEUTICS Corp
- CPIXCUMBERLAND PHARMACEUTICALS INC
- LLYELI LILLY & Co
- ALNYALNYLAM PHARMACEUTICALS, INC.
- PTCTPTC THERAPEUTICS, INC.
- MDGLMADRIGAL PHARMACEUTICALS, INC.
- ONCBeOne Medicines Ltd.
- IONSIONIS PHARMACEUTICALS INC
- INSMINSMED Inc
- CORTCORCEPT THERAPEUTICS INC
- BBIOBridgeBio Pharma, Inc.
- CYTKCYTOKINETICS INC
- VRTXVERTEX PHARMACEUTICALS INC / MA
- LGNDLIGAND PHARMACEUTICALS INC
- LQDALiquidia Corp
- SIONSionna Therapeutics, Inc.
- JAZZJazz Pharmaceuticals plc
- BLTEBELITE BIO, INC
- TVTXTravere Therapeutics, Inc.
- PAHCPHIBRO ANIMAL HEALTH CORP
- ARQTArcutis Biotherapeutics, Inc.
- NATRNATURES SUNSHINE PRODUCTS INC
- HOWLWerewolf Therapeutics, Inc.
- JNJJOHNSON & JOHNSON
Datasets
Frequently Asked Questions
How much of ROIV is sold short?
What is ROIV's daily short volume?
Does ROIV have fails to deliver?
Are ROIV insiders buying or selling?
Have ROIV insiders filed to sell?
What did ROIV report last quarter?
Which funds hold ROIV?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.